Bangladeshi drug company Globe Biotech Ltd has sought permission for clinical trial of its Bangavax Covid-19 vaccine.
It submitted an application to Bangladesh Medical Research Council on Sunday in this regard.
Chairman of Globe Pharmaceuticals Ltd Harunur Rashid and other senior officials submitted the application for ethical clearance.
CRO Ltd will carry out the clinical trial of the homegrown vaccine. The trial will be conducted at a government hospital. The name of the hospital will be announced after getting the permission for trial.
Earlier on December 28, Globe Biotech was allowed to produce Bangavax vaccine for experimental trial.
The World Health Organization (WHO) enlisted three types of the Bangladeshi vaccine candidate, initially named Bancovid.
It included the three types -- D614G variant LNP-encapsulated mRNA, DNA plasmid vaccine and Adenovirus Type 5 Vector -– in the draft landscape of COVID-19 candidate vaccines.
The first D614G variant mRNA-based vaccine candidate against Sars-CoV-2 developed by the Bangladeshi pharmaceutical company elicits neutralising antibody and balanced cellular immune response, according to US medical journal bioRxiv.
Globe Biotech joined the global race to develop a coronavirus vaccine in the country as the first company of Bangladesh.
The animal trials of its vaccine have already been completed.